Status:
COMPLETED
COVID-SErology in Rheumatoid Arthritis (COVID-19)
Lead Sponsor:
University Hospital, Montpellier
Conditions:
COVID-19
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
Due to the Covid-19 worldwide outbreak, fragile patients with immune diseases, notably rheumatoid arthritis (RA), have to be even more specifically and carefully followed-up. However, it has been show...
Detailed Description
Rheumatoid arthritis (RA) is the most common inflammatory rheumatism, affecting 0.5% to 1% of the European population. Characterized by symmetrical and distal erosive polyarthritis, its diagnosis is b...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- \- Samples from a pre-July 2019 RA patient biobank to ensure true negativity of Covid -19 (patients over 18 years old)
- Exclusion criteria:
- \- Patients who have traveled to China or Saudi Arabia and therefore may have encountered other coronaviruses.
Exclusion
Key Trial Info
Start Date :
May 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2020
Estimated Enrollment :
216 Patients enrolled
Trial Details
Trial ID
NCT04407559
Start Date
May 1 2020
End Date
September 30 2020
Last Update
December 29 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Uhmontpellier
Montpellier, France, 34295